Abstract | BACKGROUND: METHODS: RESULTS: After two cycles of chemotherapy, the clinical tumor response was complete in 31 percent of the patients and partial in 54 percent. After a median follow-up of 33 months, the estimated 2-year survival was 68 percent (95 percent confidence interval, 60 to 76 percent) for both treatment groups (P = 0.9846). Patterns of recurrence differed significantly between the two groups, with more local recurrences (P = 0.0005) and fewer distant metastases (P = 0.016) in the chemotherapy group than in the surgery group. A total of 59 patients in the chemotherapy group (36 percent) required total laryngectomy. The larynx was preserved in 64 percent of the patients overall and 64 percent of the patients who were alive and free of disease. CONCLUSIONS:
|
Authors | Department of Veterans Affairs Laryngeal Cancer Study Group, Gregory T Wolf, Susan Gross Fisher, Waun Ki Hong, Robert Hillman, Monica Spaulding, George E Laramore, James W Endicott, Kenneth McClatchey, William G Henderson |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 324
Issue 24
Pg. 1685-90
(06 13 1991)
ISSN: 0028-4793 [Print] United States |
PMID | 2034244
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Squamous Cell
(radiotherapy, therapy)
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Laryngeal Neoplasms
(radiotherapy, therapy)
- Laryngectomy
- Male
- Middle Aged
- Neoplasm Recurrence, Local
- Prospective Studies
- Survival Rate
|